• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Zebra Technologies to Acquire Temptime Corporation

Share:

February 3, 2019

Zebra Technologies Corporation, an innovator at the edge of the enterprise with solutions and partners that enable businesses to gain a performance edge, today announced that it intends to acquire Temptime Corporation, a privately-held developer and manufacturer of temperature monitoring solutions for mission-critical applications in the healthcare industry.

Founded in 1987, Temptime is the leading developer of highly differentiated technology with approximately 90 issued patents in place. This technology visually notifies users if medical and biological products and shipments have experienced a temperature deviation. Temptime is the leader in designing and manufacturing a time-temperature monitoring product portfolio that meets the strict specifications of the largest global health organizations’ vaccination programs. Temptime serves every global manufacturer that participates in these programs.

“The acquisition of Temptime advances the integration of smart supplies into our Enterprise Asset Intelligence vision as we incorporate temperature-monitoring capabilities,” said Anders Gustafsson, chief executive officer of Zebra Technologies. “This acquisition aligns well with our strategy to expand into high-growth areas that are a strong fit for Zebra. We have the unique ability to scale this technology deeper into the healthcare industry and drive it into other key opportunities such as food safety that can benefit from increased asset visibility.”

“We are very excited to join Zebra and work together to advance our technology from visual to digital temperature indicators. This will enable us to more quickly accelerate our innovation to benefit our customers,” said Renaat Van den Hooff, president and chief executive officer of Temptime, who will be a key leader in the business integration. “Zebra’s expertise in healthcare complements our commitment to supporting our humanitarian mission of improving global health.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Zebra expects to fund the acquisition of Temptime with a combination of cash on hand along with fully committed financing available under its credit facility. Zebra expects this transaction to be immediately accretive to earnings. The transaction is subject to customary closing conditions, including regulatory approvals and is expected to close in the first quarter of 2019. Financial terms of the acquisition are not being disclosed.

Zebra Technologies Safe Harbor Statement

This press release contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements regarding the company’s outlook and the ability to complete the acquisition of Temptime. Actual results may differ from those expressed or implied in the company’s forward-looking statements. These statements represent estimates only as of the date they were made. Zebra undertakes no obligation, other than as may be required by law, to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason after the date of this release.

These forward-looking statements are based on current expectations, forecasts and assumptions and are subject to the risks and uncertainties inherent in Zebra’s industry, market conditions, general domestic and international economic conditions, and other factors. These factors include customer acceptance of Zebra’s hardware and software products and competitors’ product offerings, and the potential effects of technological changes. The continued uncertainty over future global economic conditions, the availability of credit and capital markets volatility may have adverse effects on Zebra, its suppliers and its customers. In addition, a disruption in our ability to obtain products from vendors as a result of supply chain constraints, natural disasters or other circumstances could restrict sales and negatively affect customer relationships. Profits and profitability will be affected by Zebra’s ability to control manufacturing and operating costs. Because of its debt, interest rates and financial market conditions will also have an impact on results. Foreign exchange rates will have an effect on financial results because of the large percentage of our international sales. The outcome of litigation in which Zebra may be involved is another factor. The success of integrating acquisitions could also affect profitability, reported results and the company’s competitive position in its industry. These and other factors could have an adverse effect on Zebra’s sales, gross profit margins and results of operations and increase the volatility of our financial results. When used in this release and documents referenced, the words “anticipate,” “believe,” “outlook,” and “expect” and similar expressions, as they relate to the company or its management, are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. Descriptions of the risks, uncertainties and other factors that could affect the company’s future operations and results can be found in Zebra’s filings with the Securities and Exchange Commission, including the company’s most recent Form 10-K.

Date: February 4, 2019

Source: Yahoo Finance

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative PainFlexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
  • Merck Completes Tender Offer to Acquire Imago BioSciences, IncMerck Completes Tender Offer to Acquire Imago BioSciences, Inc
  • Amplifybio Acquires Pact Pharma Assets to Enhance Cell and Gene Therapy Characterization CapabilitiesAmplifybio Acquires Pact Pharma Assets to Enhance Cell and Gene Therapy Characterization Capabilities
  • Cigna Completes Combination with Express Scripts, Establishing a Blueprint to Transform the Health Care SystemCigna Completes Combination with Express Scripts, Establishing a Blueprint to Transform the Health Care System
  • Foundation Medicine Acquires Lexent Bio, Inc., to Accelerate Liquid Biopsy Research and Development, and Advance Cancer CareFoundation Medicine Acquires Lexent Bio, Inc., to Accelerate Liquid Biopsy Research and Development, and Advance Cancer Care
  • Indonesia’s Largest Single-payer System BPJS Kesehatan Teams up with Local Health Apps Startup Halodoc to Improve Equal Access to Health Care Across the CountryIndonesia’s Largest Single-payer System BPJS Kesehatan Teams up with Local Health Apps Startup Halodoc to Improve Equal Access to Health Care Across the Country
  • Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of LicenseTNX-1900 Intranasal Oxytocin has the Potential to Treat Migraine and Craniofacial PainTonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of LicenseTNX-1900 Intranasal Oxytocin has the Potential to Treat Migraine and Craniofacial Pain
  • Roche Delays Spark Buyout Again as U.S. and U.K. Regulators Continue to Review The DealRoche Delays Spark Buyout Again as U.S. and U.K. Regulators Continue to Review The Deal

Trending This Week

  • New tools and acquisitions from OptumRx, ScionHealth.
  • In the wake of Dobbs, women’s health is ‘Ripe for investment’
  • Market Skeptical Following Sen. Warren’s Antitrust Allegations
  • Rogers, Shaw tick lower amid a report that Industry Minister in no hurry to Ok deal
  • ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, furthering its Ambition to Become the Global Leader in Regenerative Therapies
  • Nemaura Enters into Letter of Intent to Acquire Healthimation, LLC to Augment proBEAT™ Launch in the U.S.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications